Evaluate Relative Bioavailability of PA32540 (Asa/Omeprazole), Its Aspirin Component, and Ecotrin® in Healthy Volunteers
Information source: Pozen
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: PA32540 (Drug); aspirin component of PA32540 (Drug); Ecotrin (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Pozen
Summary
Study to determine a single dose bioavailablity of PA32540 is similar to EC aspirin 325 mg
with respect to salicylic acid.
Clinical Details
Official title: A Phase 1, Open-Label, Randomized, 3-Way Crossover Study to Evaluate the Relative Bioavailability of a Single Oral Dose of Aspirin Administered as PA32540 (Aspirin/Omeprazole) or as the Aspirin Component of PA32540 or as Ecotrin® 325 mg in Healthy Volunteers
Study design: Randomized, Open Label, Active Control, Crossover Assignment, Pharmacokinetics Study
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Standard for PK
- Ages 18-55 years old
- Males and females
Exclusion Criteria:
- Standard for PK
Locations and Contacts
Additional Information
Starting date: February 2008
Ending date: February 2008
Last updated: March 7, 2008
|
